NOX inhibitor-focused Genkyotex plans IPO
This article was originally published in Scrip
Genkyotex, a Swiss biotech developing selective NOX inhibitors, has raised CHF20m ($21m) in a series D financing. The money will fund the completion of a Phase II trial of GKT137831 in diabetic nephropathy, advance a second drug into Phase 1 trials, and broaden the company's pipeline of NOX inhibitors. If all goes to plan, the company plans to seek an initial public offering later this year if the markets are still welcoming.